Skip to content

Long-term therapeutic evaluation of two types of platelet-rich plasma treatments for early knee osteoarthritis in middle-aged patients (PORT): a prospective, double-blind, randomised, Chinese multi-centre clinical trial

Long-term therapeutic evaluation of two types of platelet-rich plasma treatments for early knee osteoarthritis in middle-aged patients (PORT): a prospective, double-blind, randomised, Chinese multi-centre clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800020084
Enrollment
Unknown
Registered
2018-12-13
Start date
2020-07-01
Completion date
Unknown
Last updated
2020-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Interventions

Sponsors

Shanghai Jiaotong University Affiliated Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: All consenting knee OA patients meeting the following criteria are screened for inclusion: 1. between the ages of 40 years and 70 years old (non-inclusive); 2. who have had bilateral knee pain persisting for more than 6 months (also present for most of previous month); 3. have Kellgren and Lawrence grade 2 or 3 knee OA (documented by anteroposterior and lateral view X-rays); 4. have completed physical therapy for at least 3 months; and 5. are able to communicate in Mandarin Chinese.

Exclusion criteria

Exclusion criteria: 1. Candidate participant has co-morbidities, such as systemic or inflammatory joint disease (rheumatoid arthritis); history of crystalline arthritis (gout and pseudogout) or neurological joint disease (neuroarthropathies, Charcot joint); other muscle, joint, or nervous system diseases that affect lower limb function; 2. has needle phobia; 3. has evidence of immunosuppression or acute infection; 4. has or has had cancer or tumours; 5. has a bleeding disorder or is receiving anticoagulation or antiplatelet therapy; 6. has a platelet count of = 6.2 mmol/L and triglycerides of > 2.3 mmol/L; 8. presence of other medical conditions that preclude participation, including contraindications to MRI, such as pacemaker, ferromagnetic aneurysm clips, cochlear implant, or any other metallic foreign bodies; 9. pregnant; 10. has a body mass index (BMI) of > 40 kg/m2; 11. unable to make at least 10 research appointments within 24 months; 12. has a history of any mental illness.

Design outcomes

Primary

MeasureTime frame
WOMAC scale;Volume of medial tibial cartilage;

Secondary

MeasureTime frame
Severity of knee pain during walking;Intermittent and persistent osteoarthritis pain;Knee joint injury and OA outcome score;The amount of celecoxib taken orally;

Countries

China

Contacts

Public ContactZhang Changqing

Shanghai Jiaotong University Affiliated Sixth People's Hospital

zhangcq@sjtu.edu.cn+86 13918385701

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026